2026 BD opportunity scan for Antengene Corp. Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for AnHeart Therapeutics LLC: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Altesa BioSciences, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for AlphaNa Bioscience Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale

2026 BD opportunity scan for Alkermes, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Akeso Biopharma Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Addpharma, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for ADARx Pharmaceuticals, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Actuate Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for AbelZeta Pharma, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

NCT07446452 clinical trial report covering Disitamab Vedotin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

NCT07444892 clinical trial report covering Levodopa hydrate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.